RNA genomics firm Eclipsebio acquired Terrain Bio to integrate machine‑learning RNA analytics into a sequencing‑first platform for RNA therapeutic design and manufacturing. Eclipsebio said the acquisition will enable iterative design, high‑resolution measurement of structure/translation/impurities, and improved manufacturing robustness and quality‑by‑design. CEO Peter Chu framed the deal as accelerating Eclipsebio’s move earlier into design and validation for RNA drug developers; financial terms were not disclosed.